查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1634208

全球消融设备市场 - 2025 - 2033

Global Ablation Devices Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 159 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球消融器械市场规模达62亿美元，预计2033年将达到141亿美元，2025-2033年预测期间复合年增长率为9.7%。

消融装置是用于各种治疗过程中的专用医疗器械，透过定向能量去除、破坏或治疗异常或患病组织。这些设备通常用于微创手术，提供精确且受控的治疗方法，对周围健康组织的损害最小。消融通常使用各种形式的能量来进行，例如热、冷、电或光。消融设备在现代医学中发挥着至关重要的作用，为各种医疗状况的患者提供更安全、更有效、更侵入性的治疗选择。

在消融设备的进步、产品发布的增加以及对微创手术的日益偏好的推动下，消融设备市场正在经历显着增长。例如，2024 年 10 月，雅培实现了新的重大里程碑，以支持公司不断增长的电生理学脉衝场消融 (PFA) 解决方案套件：提前完成支援 Volt PFA 系统的 VOLT-AF IDE 研究的註册，并推出FOCALFLEX 试验旨在评估该公司的TactiFlex Duo 消融导管、感测器启用(SE)，该导管将用于治疗阵发性心房颤动患者。

市场动态：

驱动程式和限制

消融设备技术不断进步

消融设备不断进步的技术进步极大地推动了消融设备市场的成长，预计将在预测期内推动市场成长。技术进步，特别是影像和导引系统的进步，大大提高了消融手术的精确度。这些创新扩大了应用范围，减少了手术时间，改善了患者的治疗效果，并扩大了微创选择的范围。

先进电解剖测绘系统的整合彻底改变了其在心臟病学中的应用，特别是在治疗心房颤动方面。精确绘製心臟电活动图的能力可以提高治疗后的成功率并降低心律不整的復发率。

例如，2024 年10 月，波士顿科学公司获得美国食品药物管理局(FDA) 批准用于治疗阵发性心房颤动(AF) 的具有导航功能的FARAWAVE NAV 消融导管，并获得FDA 510(k) 批准用于新型FARAVIEW该软体将与 FARAPULSE 脉衝场消融 (PFA) 系统结合，为心臟消融手术提供可视化。

此外，2024 年10 月，美敦力(Medtronic) 宣布美国食品和药物管理局(FDA) 批准配备Sphere-9 导管的Affera 标测和消融系统，这是一款一体化、高密度(HD) 标测和脉衝场(PF) 和射频 (RF) 消融导管，用于治疗持续性心房颤动 (AFib) 和射频消融三尖瓣峡部 (CTI) 依赖性心房扑动。

机器人辅助消融系统正在提高手术的准确性和控制。例如，2024年12月，Stereotaxis Inc.和中国合作伙伴上海微创环保医疗科技有限公司的Magbot磁导航消融导管获得国家药品监督管理局批准，与Stereotaxis的机器人消融系统一起使用，治疗抗药性心律失常在中国。

潜在的副作用和併发症

与消融手术相关的潜在副作用和併发症是消融设备市场成长的重大挑战。这些风险可能会阻止患者和医疗保健提供者采用消融技术，从而限制其广泛使用。例如，在射频或冷冻消融治疗心房颤动期间，有造成食道损伤或对附近神经（例如膈神经）造成附带损伤的风险，从而导致呼吸困难等併发症。

侵入性手术，例如基于导管的消融术，有插入部位感染和出血的风险。例如，肝臟肿瘤的微波消融（MWA）或射频消融（RFA）与术后感染和出血有关，特别是对于预先存在肝功能障碍或凝血病的患者。

此外，用于换肤或除皱的雷射消融设备有时会导致表面烧伤或疤痕，引起患者的不满并损害此类设备在美容应用中的声誉。

消融疗法，尤其是心律不整和某些肿瘤的消融疗法，可能不会总是提供永久性的结果，从而导致病情復发。例如，接受消融治疗的心房颤动患者可能在几年内復发心律不整，需要重复手术或替代治疗。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 技术片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 消融设备不断进步的技术
    • 限制
      • 潜在的副作用和併发症
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：消融设备市场（按技术）

  • 射频消融术
  • 微波消融
  • 冷冻消融
  • 超音波消融
  • 雷射/光烧蚀
  • 电消融
  • 其他的

第 6 章：消融设备市场（按应用）

  • 癌症
  • 眼科
  • 心血管
  • 泌尿科
  • 骨科
  • 妇科
  • 美容/整容手术
  • 疼痛管理
  • 其他的

第 7 章：消融设备市场（依最终用户）

  • 医院
  • 手术中心
  • 美容诊所
  • 门诊手术中心
  • 其他的

第 8 章：消融设备市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 9 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 10 章：公司简介

  • Abbott Laboratories
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • Boston Scientific Corporation
  • Medtronic plc
  • Johnson & Johnson
  • Olympus Corporation
  • Stryker Corporation
  • Hologic, Inc.
  • CONMED Corporation
  • Koninklijke Philips NV
  • CooperSurgical, Inc.

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD861

The global ablation devices market reached US$ 6.2 billion in 2024 and is expected to reach US$ 14.1 billion by 2033, growing at a CAGR of 9.7% during the forecast period 2025-2033.

Ablation devices are specialized medical instruments used in various therapeutic procedures to remove, destroy, or treat abnormal or diseased tissue through targeted energy. These devices are often used in minimally invasive procedures, offering precise and controlled methods of treatment with minimal damage to surrounding healthy tissues. Ablation is typically performed using various forms of energy such as heat, cold, electricity, or light. Ablation devices play a critical role in modern medicine, providing patients with safer, more efficient, and less invasive treatment options for a variety of medical conditions.

The ablation devices market is experiencing significant growth, driven by advancements in ablation devices, rising product launches and an increasing preference for minimally invasive procedures. For instance, in October 2024, Abbott achieved new major milestones to support the company's growing suite of pulsed-field ablation (PFA) solutions in electrophysiology: early completion of enrollment in the VOLT-AF IDE Study supporting the Volt PFA System and the launch of the FOCALFLEX trial to assess the company's TactiFlex Duo Ablation Catheter, Sensor Enabled (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation.

Market Dynamics: Drivers & Restraints

Rising technological advancements in ablation devices

The rising technological advancements in ablation devices are significantly driving the growth of the Ablation Devices market and are expected to drive the market over the forecast period. Technological advancements, particularly in imaging and guidance systems, have greatly enhanced the precision of ablation procedures. These innovations are broadening the scope of applications, reducing procedure times, improving patient outcomes, and expanding access to minimally invasive options.

The integration of advanced electroanatomical mapping systems has revolutionized its use in cardiology, especially for treating atrial fibrillation. The ability to map the heart's electrical activity with precision has led to better success rates and lower recurrence of arrhythmias after treatment.

For instance, in October 2024, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) and FDA 510(k) clearance for the new FARAVIEW Software, which will combine to provide visualization for cardiac ablation procedures with the FARAPULSE Pulsed Field Ablation (PFA) System.

Additionally, in October 2024, Medtronic plc announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density (HD) mapping and pulsed-field (PF) and radiofrequency (RF) ablation catheter for treatment of persistent atrial fibrillation (AFib) and for RF ablation of cavotricuspid isthmus (CTI) dependent atrial flutter.

Robotic-assisted ablation systems are improving the accuracy and control of procedures. For instance, in December 2024, Stereotaxis Inc. and Chinese partner Shanghai Microport EP Medtech Co. Ltd. gained the National Medical Products Administration's approval of its Magbot magnetic navigation ablation catheter for use with Stereotaxis' robotic ablation system to treat drug-resistant cardiac arrhythmias in China.

Potential side effects and complications

Potential side effects and complications associated with ablation procedures are a significant challenge to the growth of the ablation devices market. These risks can deter patients and healthcare providers from adopting ablation technologies, limiting their widespread use. For instance, during radiofrequency or cryoablation for atrial fibrillation, there is a risk of causing esophageal injury or collateral damage to nearby nerves, such as the phrenic nerve, leading to complications like difficulty breathing.

Invasive procedures, such as catheter-based ablations, carry a risk of infection and bleeding at the insertion site. For instance, microwave ablation (MWA) or radiofrequency ablation (RFA) for liver tumors has been associated with post-procedural infections and bleeding, particularly in patients with pre-existing liver dysfunction or coagulopathies.

Additionally, laser ablation devices used for skin resurfacing or wrinkle reduction can sometimes lead to superficial burns or scarring, causing dissatisfaction among patients and tarnishing the reputation of such devices in cosmetic applications.

Ablation therapies, particularly for cardiac arrhythmias and certain tumors, may not always provide permanent results, leading to condition recurrence. For instance, atrial fibrillation patients treated with ablation may experience arrhythmia recurrence within a few years, requiring repeat procedures or alternative treatments.

Segment Analysis

The global ablation devices market is segmented based on technology, application, end-user and region.

Technology:

The radiofrequency ablation segment is expected to dominate the ablation devices market share

In cardiac ablation, radiofrequency ablation is most commonly used to treat atrial fibrillation (AF) and other arrhythmias by destroying or isolating the abnormal electrical pathways in the heart. The global prevalence of AF is increasing, leading to a growing demand for radiofrequency ablation devices. For instance, according to the National Institute of Health (NIH), the worldwide prevalence of atrial fibrillation is 37,574 million cases (0.51% of the worldwide population), increased by 33% during the last 20 years.

Radiofrequency ablation is also used in the treatment of chronic pain by targeting nerves that cause pain. It is especially used in conditions like osteoarthritis and back pain. This versatility in treating various pain conditions across multiple specialties has helped solidify radiofrequency ablation's market dominance. For instance, in July 2024, Stryker launched the MultiGen 2 Radiofrequency (RF) Generator, this technology provides physicians with the efficiency, control and reliability they need when performing RF ablation, a minimally invasive procedure that can provide lasting relief to those suffering from facet joint pain.

Advances in radiofrequency ablation technology, such as the development of more precise catheter designs, multi-electrode systems, and integrated mapping systems, have contributed to its increased efficiency and safety. For instance, in April 2024, a Minnesota-based medical technology company launched its OneRF Ablation System, which creates radiofrequency lesions in nervous tissue for functional neurosurgical procedures. According to a release from NeuroOne Medical Technologies, this system is the company's first device with a therapeutic indication. The thin-film, stereoelectroencephalopathy-guided radio frequency system is capable of both recording electrical activity and ablating nervous tissue while offering temperature control during surgical procedures.

Geographical Analysis

North America is expected to hold a significant position in the ablation devices market share

North America, particularly the United States, is a global leader in the development and adoption of cutting-edge medical technologies. Many of the world's leading companies in the ablation devices market are based in North America, including Medtronic, Boston Scientific and Johnson & Johnson, which are pioneers in radiofrequency, cryoablation and microwave ablation technologies. The region continues to invest heavily in research and development, driving innovation in ablation devices.

For instance, in November 2024, Johnson & Johnson MedTech announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform for the treatment of drug-refractory paroxysmal Atrial Fibrillation (AFib). The VARIPULSE Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO 3 Electro-anatomical Mapping System, driving efficiency, reproducibility and accuracy.

The U.S. Food and Drug Administration (FDA) plays a critical role in the regulatory approval of medical devices, and its rigorous yet supportive framework for innovative technologies has helped speed up the availability of new ablation devices. Devices such as Medtronic's Arctic Front Cryoballoon and Biosense Webster's ThermoCool SmartTouch Catheter have received FDA approval, ensuring that North America remains at the forefront of adopting the latest and most advanced ablation technologies. This rising FDA approvals of advanced ablation devices is driving the market in the region.

For instance, in August 2023, Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced that several products in its market-leading cardiac ablation portfolio have received approval for a zero fluoroscopy workflow from the U.S. Food and Drug Administration (FDA). The products that can be used in this workflow include: THERMOCOOL SMARTTOUCH SF catheter, the most commonly used ablation catheter in the world for RF ablation, THERMOCOOL SMARTTOUCH Catheter, CARTO VIZIGO Bi-Directional Guiding Sheath, PENTARAY NAV ECO High-Density Mapping Catheter, DECANAV Mapping Catheters, and Webster CS Catheter.

Asia-Pacific is growing at the fastest pace in the ablation devices market

The prevalence of chronic conditions, such as cardiovascular diseases (CVDs), cancer and diabetes, is rapidly increasing in the Asia-Pacific region, fueling the demand for ablation therapies. Conditions like atrial fibrillation and liver cancer are becoming more common, and ablation is a preferred treatment for these diseases due to its minimally invasive nature.

For instance, as the incidence of cancer increases, particularly liver, lung and kidney cancers, the need for tumor ablation devices is also rising. The World Health Organization (WHO) forecasts that cancer cases in India will rise by 40% by 2030, further driving demand for ablation therapies.

The Asia Pacific region is seeing significant improvements in healthcare infrastructure, especially in countries like China, India, Japan, South Korea, and Australia. These countries are investing heavily in modern healthcare technologies, leading to increased adoption of advanced medical devices, including ablation technologies. Many hospitals and healthcare facilities are expanding their capacity to provide cutting-edge treatments, driving the demand for ablation devices.

For instance, in September 2024, Kauvery Hospital launched Fluoroless Ablation for Atrial Fibrillation, setting a new benchmark in the treatment of one of the most common heart rhythm disorders. Kauvery Hospital continues to push the boundaries of medical innovation to ensure that patients receive the most effective and minimally invasive treatments available.

Competitive Landscape

The major global players in the ablation devices market include Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Johnson & Johnson, Olympus Corporation, Stryker Corporation, Hologic, Inc., CONMED Corporation, Koninklijke Philips N.V., CooperSurgical, Inc. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global ablation devices market report delivers a detailed analysis with 62 key tables, more than 64 visually impactful figures, and 187 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Technology
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Ablation Devices
    • 3.1.2. Restraints
      • 3.1.2.1. Potential Side Effects and Complications
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Ablation Devices Market, By Technology

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 5.1.2. Market Attractiveness Index, By Technology
  • 5.2. Radiofrequency Ablation*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Microwave Ablation
  • 5.4. Cryoablation
  • 5.5. Ultrasound Ablation
  • 5.6. Laser/Light Ablation
  • 5.7. Electrical Ablation
  • 5.8. Others

6. Ablation Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Cancer*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Ophthalmology
  • 6.4. Cardiovascular
  • 6.5. Urology
  • 6.6. Orthopedic
  • 6.7. Gynecology
  • 6.8. Aesthetic/Cosmetic Surgery
  • 6.9. Pain Management
  • 6.10. Others

7. Ablation Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Surgical Centers
  • 7.4. Aesthetic Clinics
  • 7.5. Ambulatory Surgical Centers
  • 7.6. Others

8. Ablation Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott Laboratories*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Boston Scientific Corporation
  • 10.3. Medtronic plc
  • 10.4. Johnson & Johnson
  • 10.5. Olympus Corporation
  • 10.6. Stryker Corporation
  • 10.7. Hologic, Inc.
  • 10.8. CONMED Corporation
  • 10.9. Koninklijke Philips N.V.
  • 10.10. CooperSurgical, Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us